StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.29−0.36 (-2.64%)

Close on Nov 16, 2026Market cap $1.89BP/E –Yield –

Trevi Therapeutics cash

Cash and short-term investments held at the end of each period.

Trevi Therapeutics's cash was $318.87M at Jun 30, 2026. For fiscal 2025 it was $188.26M, up 74.9% from the year before. The highest annual figure on record is $188.26M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$188.26M+74.9%
FY2024Dec 31, 2024$107.62M+29.7%
FY2023Dec 31, 2023$82.97M-31.2%
FY2022Dec 31, 2022$120.51M+227.2%
FY2021Dec 31, 2021$36.83M-18.2%
FY2020Dec 31, 2020$45.00M-21.5%
FY2019Dec 31, 2019$57.31M+695.8%
FY2018Dec 31, 2018$7.20M-67.3%
FY2017Dec 31, 2017$22.02M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$318.87M+56.4%
Q1 FY2026Mar 31, 2026$171.78M+66.4%
Q4 FY2025Dec 31, 2025$188.26M+74.9%
Q3 FY2025Sep 30, 2025$194.93M+197.6%
Q2 FY2025Jun 30, 2025$203.89M+193.4%
Q1 FY2025Mar 31, 2025$103.26M+41.8%
Q4 FY2024Dec 31, 2024$107.62M+29.7%
Q3 FY2024Sep 30, 2024$65.49M-26.3%
Q2 FY2024Jun 30, 2024$69.50M-26.2%
Q1 FY2024Mar 31, 2024$72.82M-34.5%
Q4 FY2023Dec 31, 2023$82.97M-31.2%
Q3 FY2023Sep 30, 2023$88.87M-29.2%
Q2 FY2023Jun 30, 2023$94.15M+20.9%
Q1 FY2023Mar 31, 2023$111.26M+282.2%
Q4 FY2022Dec 31, 2022$120.51M+227.2%
Q3 FY2022Sep 30, 2022$125.60M+328.4%
Q2 FY2022Jun 30, 2022$77.86M+113.7%
Q1 FY2022Mar 31, 2022$29.11M-30.0%
Q4 FY2021Dec 31, 2021$36.83M-18.2%
Q3 FY2021Sep 30, 2021$29.32M-45.0%
Q2 FY2021Jun 30, 2021$36.43M-17.6%
Q1 FY2021Mar 31, 2021$41.57M-21.0%
Q4 FY2020Dec 31, 2020$45.00M-21.5%
Q3 FY2020Sep 30, 2020$53.29M-16.1%
Q2 FY2020Jun 30, 2020$44.18M-38.1%
Q1 FY2020Mar 31, 2020$52.64M+306.6%
Q4 FY2019Dec 31, 2019$57.31M+695.8%
Q3 FY2019Sep 30, 2019$63.52M+369.3%
Q2 FY2019Jun 30, 2019$71.39M+911.4%
Q1 FY2019Mar 31, 2019$12.95M-18.9%
Q4 FY2018Dec 31, 2018$7.20M-67.3%
Q3 FY2018Sep 30, 2018$13.53M–
Q2 FY2018Jun 30, 2018$7.06M–
Q1 FY2018Mar 31, 2018$15.96M–
Q4 FY2017Dec 31, 2017$22.02M–

More Trevi Therapeutics figures

See a number that looks wrong?